Common Contracts
9 similar null contracts by Regenerx Biopharmaceuticals Inc, Essetifin SPA
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKEssetifin SPA • July 6th, 2023 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, Essetifin S.p.A., or its permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) up to 3,750,000 shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated of even date herewith (the “Purchase Agreement”).
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKRegenerx Biopharmaceuticals Inc • November 13th, 2020 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, _____________, or his permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) up to _____________shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated of even date herewith (the “Purchase Agreement”).
ContractEssetifin SPA • October 16th, 2020 • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKRegenerx Biopharmaceuticals Inc • May 15th, 2019 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, _______________, or his permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) up to 78,125 shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated of even date herewith (the “Purchase Agreement”).
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKRegenerx Biopharmaceuticals Inc • January 7th, 2011 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, [NAME OF INVESTOR], or its permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) up to ________ shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated of even date herewith (the “Purchase Agreement”).
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKRegenerx Biopharmaceuticals Inc • October 5th, 2009 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, CHAUMIERE-CONSULTADORIA & SERVICOS SDC UNIPESSOAL LDA, or its permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) up to 609,756 shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated as of September 30, 2009 (the “Purchase Agreement”).
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKRegenerx Biopharmaceuticals Inc • April 16th, 2009 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, Chaumiere-Consultadoria & Servicos SDC Unipessoal LDA, or its permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, Inc., a Delaware corporation (the “Company”) up to 263,158 shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated as of April 13, 2009 (the “Purchase Agreement”).
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKRegenerx Biopharmaceuticals Inc • December 12th, 2008 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, , or permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, Inc., a Delaware corporation (the “Company”) up to ( ) shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated as of the date hereof (the “Purchase Agreement”).
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKRegenerx Biopharmaceuticals Inc • February 27th, 2008 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, , or permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, Inc., a Delaware corporation (the “Company”) up to five-hundred thousand (500,000) shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated as of the date hereof (the “Purchase Agreement”).
